E-moxiclav 457 mg / 5 ml powder for suspension preparation 70 ml
Tradename
E-moxiclav
E-moxclav
Composition
Each 5 ml of suspension contains:
Amoxicillin 400 mg
Clavulanic acid 57 mg
Auxiliary components:
citric acid (anhydrous), sodium citrate (anhydrous), microcrystalline cellulose and sodium carmellose, xanthan gum, colloidal silicon dioxide, silicon dioxide, orange flavor, sodium saccharinate, mannitol.
Properties
Combined preparation of amoxicillin and clavulanic acid — a beta-lactamase inhibitor. Acts bactericidal, inhibits the synthesis of the bacterial wall.
Active against aerobic gram-positive bacteria (including strains producing beta-lactamases): Staphylococcus aureus; aerobic gram-negative bacteria: Enterobacter spp., Escherichia coli, Haemophilus influenzae, Klebsiella spp., Moraxella catarrhalis. The following pathogens are sensitive only in vitro: Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus anthracis, Streptococcus pneumoniae, Streptococcus viridans, Enterococcus faecalis, Corynebacterium spp., Listeria monocytogenes; anaerobic Clostridium spp., Peptococcus spp., Peptostreptococcus spp .; as well as aerobic gram-negative bacteria (including strains producing beta-lactamases): Proteus mirabilis, Proteus vulgaris, Salmonella spp., Shigella spp., Bordetella pertussis, Yersinia enterocolitica, Gardnerella vaginalis, Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus ducreyi, Yersinia multocida (formerly Pasteurella), Campylobacter jejuni; anaerobic gram-negative bacteria (including strains producing beta-lactamases): Bacteroides spp., including Bacteroides fragilis. Clavulanic acid inhibits types II, III, IV and V beta-lactamases, is inactive against type I beta-lactamases produced by Pseudomonas aeruginosa, Serratia spp., Acinetobacter spp. Clavulanic acid has a high tropism for penicillinases, due to which it forms a stable complex with the enzyme, which prevents the enzymatic degradation of amoxicillin under the influence of beta-lactamases. Clavulanic acid inhibits types II, III, IV and V beta-lactamases, is inactive against type I beta-lactamases produced by Pseudomonas aeruginosa, Serratia spp., Acinetobacter spp. Clavulanic acid has a high tropism for penicillinases, due to which it forms a stable complex with the enzyme, which prevents the enzymatic degradation of amoxicillin under the influence of beta-lactamases. Clavulanic acid inhibits types II, III, IV and V beta-lactamases, is inactive against type I beta-lactamases produced by Pseudomonas aeruginosa, Serratia spp., Acinetobacter spp. Clavulanic acid has a high tropism for penicillinases, due to which it forms a stable complex with the enzyme, which prevents the enzymatic degradation of amoxicillin under the influence of beta-lactamases.
Indications
Treatment of infectious and inflammatory diseases caused by sensitive pathogens: lower respiratory tract infections (bronchitis, pneumonia, pleural empyema, lung abscess); ENT infections (sinusitis, tonsillitis, otitis media); infections of the genitourinary system and pelvic organs (pyelonephritis, pyelitis, cystitis, urethritis, prostatitis, cervicitis, salpingitis, salpingo-oophoritis, tubo-ovarian abscess, endometritis, bacterial vaginitis, septic abortion, postpartum sepsis, pelvioperitonitis, soft chancre); infections of the skin and soft tissues (erysipelas, impetigo, secondarily infected dermatoses, abscess, phlegmon, wound infection); osteomyelitis; postoperative infections. Prevention of infections in surgery.
Method of administration and dosage:
Doses are given in terms of amoxicillin. The dosage regimen is set individually, depending on the severity of the course and localization of the infection, the sensitivity of the pathogen. Children under 12 years old — in the form of a suspension, syrup is established depending on age: Children 3 months and older — with infections of mild severity — 25 mg / kg / day in 2 doses or 20 mg / kg / day in 3 doses, with severe infections — 45 mg / kg / day in 2 divided doses or 40 mg / kg / day in 3 doses. Adults and children over 12 years old or weighing 40 kg or more: 500 mg 2 times / day or 250 mg 3 times / day. For severe infections and respiratory tract infections — 875 mg 2 times / day or 500 mg 3 times / day.
Contraindications
Hypersensitivity to drug components (including cephalosporins and other beta-lactam antibiotics); infectious mononucleosis (including with the appearance of a measles-like rash); phenylketonuria; episodes of jaundice or liver dysfunction as a result of amoxicillin / clavulanic acid use in history; CC less than 30 ml / min (for tablets 875 mg / 125 mg). With caution
Pregnancy, lactation, severe liver failure, gastrointestinal diseases (including a history of colitis associated with the use of penicillins), chronic renal failure.
Precautionary measures:
Side effects
From the digestive system: nausea, vomiting, diarrhea, gastritis, stomatitis, glossitis, increased activity of hepatic transaminases, in isolated cases — cholestatic jaundice, hepatitis, liver failure (more often in the elderly, men, with prolonged therapy), pseudomembranous and hemorrhagic colitis ( can also develop after therapy), enterocolitis, black «hairy» tongue, darkening of tooth enamel.
From the side of hematopoietic organs: a reversible increase in prothrombin time and bleeding time, thrombocytopenia, thrombocytosis, eosinophilia, leukopenia, agranulocytosis, hemolytic anemia.
From the nervous system: dizziness, headache, hyperactivity, anxiety, change in behavior, seizures.